ARVN - Arvinas, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
New Haven,
United States
Type: Equity
ARVN price evolution
ARVN
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $317.2 | $119.2 | $96.1 | $135.7 |
| Short term investments | $949.3 | $884.8 | $948.2 | $993.3 |
| Net receivables | $7.2 | $20.6 | $4.8 | $4.7 |
| Inventory | ||||
| Total current assets | $1280.2 | $1033 | $1056.7 | $1148.2 |
| Long term investments | ||||
| Property, plant & equipment | $14 | $15.7 | $16.7 | $17.3 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $24.4 | $25.3 | $26.8 | $27.6 |
| Total investments | $949.3 | $884.8 | $948.2 | $993.3 |
| Total assets | $1304.6 | $1058.3 | $1083.5 | $1175.8 |
| Current liabilities | ||||
| Accounts payable | $92.2 | $91 | $74.8 | $66 |
| Deferred revenue | $549.2 | $506.1 | $540.6 | $593.8 |
| Short long term debt | $1.9 | $2.1 | $2 | $2 |
| Total current liabilities | $257.1 | $317.3 | $306.9 | $282.9 |
| Long term debt | $1.3 | $1.9 | $2.5 | $3 |
| Total noncurrent liabilities | $387.5 | $283.8 | $313 | $381.9 |
| Total debt | $3.2 | $4 | $4.5 | $5 |
| Total liabilities | $644.6 | $601.1 | $619.9 | $664.8 |
| Shareholders' equity | ||||
| Retained earnings | -$1332.7 | -$1177.9 | -$1113.9 | -$1047.3 |
| Other shareholder equity | -$3.1 | -$9.2 | -$12.2 | -$12.6 |
| Total shareholder equity | $660 | $457.2 | $463.6 | $511 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $317.2 | $86.8 | $112.8 | $588.37 |
| Short term investments | $949.3 | $1124 | $1394.3 | $100.16 |
| Net receivables | $7.2 | $8 | $25.7 | $8.44 |
| Inventory | ||||
| Total current assets | $1280.2 | $1240.2 | $1552.5 | $703.09 |
| Long term investments | ||||
| Property, plant & equipment | $14 | $17.8 | $16.6 | $14.25 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $24.4 | $28.6 | $29.1 | $14.28 |
| Total investments | $949.3 | $1124 | $1394.3 | $100.16 |
| Total assets | $1304.6 | $1268.8 | $1581.6 | $717.37 |
| Current liabilities | ||||
| Accounts payable | $92.2 | $5.7 | $31.3 | $7.12 |
| Deferred revenue | $549.2 | $623.7 | $740.5 | $45.09 |
| Short long term debt | $1.9 | $1.8 | $1.1 | $0.95 |
| Total current liabilities | $257.1 | $295.1 | $261.7 | $49.09 |
| Long term debt | $1.3 | $1 | $3.9 | $3.09 |
| Total noncurrent liabilities | $387.5 | $408.8 | $538.2 | $26.03 |
| Total debt | $3.2 | $5.5 | $5 | $4.04 |
| Total liabilities | $644.6 | $703.9 | $799.9 | $75.11 |
| Shareholders' equity | ||||
| Retained earnings | -$1332.7 | -$965.4 | -$682.9 | -$491.89 |
| Other shareholder equity | -$3.1 | -$19.2 | -$4.6 | $0.56 |
| Total shareholder equity | $660 | $564.9 | $781.7 | $642.26 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | -$43.1 | $34.6 | $54.5 | $32.5 |
| Cost of revenue | ||||
| Gross Profit | -$43.1 | $34.6 | $54.5 | $32.5 |
| Operating activities | ||||
| Research & development | $95.2 | $85.9 | $103.4 | $95.3 |
| Selling, general & administrative | $27 | $22.6 | $25.7 | $24.9 |
| Total operating expenses | $122.2 | $108.5 | $129.1 | $120.2 |
| Operating income | -$165.3 | -$73.9 | -$74.6 | -$87.7 |
| Income from continuing operations | ||||
| EBIT | -$153.2 | -$64 | -$66.9 | -$82.3 |
| Income tax expense | $1.6 | -$0.3 | -$0.4 | |
| Interest expense | ||||
| Net income | ||||
| Net income | -$154.8 | -$64 | -$66.6 | -$81.9 |
| Income (for common shares) | -$154.8 | -$64 | -$66.6 | -$81.9 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $78.5 | $131.4 | $46.7 | $21.8 |
| Cost of revenue | ||||
| Gross Profit | $78.5 | $131.4 | $46.7 | $21.8 |
| Operating activities | ||||
| Research & development | $379.7 | $315 | $180.4 | $108.36 |
| Selling, general & administrative | $100.3 | $79.6 | $61.6 | $38.3 |
| Total operating expenses | $480 | $394.6 | $242 | $146.66 |
| Operating income | -$401.5 | -$263.2 | -$195.3 | -$124.86 |
| Income from continuing operations | ||||
| EBIT | -$366.4 | -$261.6 | -$190.9 | -$119.27 |
| Income tax expense | $0.9 | $20.9 | ||
| Interest expense | $0.1 | $0.07 | ||
| Net income | ||||
| Net income | -$367.3 | -$282.5 | -$191 | -$119.33 |
| Income (for common shares) | -$367.3 | -$282.5 | -$191 | -$119.33 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$154.8 | -$64 | -$66.6 | -$81.9 |
| Operating activities | ||||
| Depreciation | $1.7 | $1.7 | $1.6 | $1.7 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $16.7 | $16.7 | $18.3 | $19.9 |
| Total cash flows from operations | -$83.1 | -$84.8 | -$88.7 | -$91.2 |
| Investing activities | ||||
| Capital expenditures | -$0.1 | -$1.1 | -$0.6 | -$1.1 |
| Investments | -$53.6 | $71.1 | $49.2 | $139.7 |
| Total cash flows from investing | -$53.7 | $70 | $48.6 | $138.6 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $334.8 | $37.9 | $0.5 | $1.5 |
| Net borrowings | ||||
| Total cash flows from financing | $334.8 | $37.9 | $0.5 | $1.5 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $198 | $23.1 | -$39.6 | $48.9 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$367.3 | -$282.5 | -$191 | -$119.33 |
| Operating activities | ||||
| Depreciation | $6.7 | $8.2 | $6 | $4.02 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $71.6 | $75.5 | $57.1 | $30.23 |
| Total cash flows from operations | -$347.8 | -$273.5 | $559.4 | -$89.76 |
| Investing activities | ||||
| Capital expenditures | -$2.9 | -$6.8 | -$4.7 | -$6.45 |
| Investments | $206.4 | $249.6 | -$1308.9 | $170.7 |
| Total cash flows from investing | $203.5 | $242.8 | -$1313.6 | $164.25 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $374.7 | $4.7 | $278.6 | $504.67 |
| Net borrowings | ||||
| Total cash flows from financing | $374.7 | $4.7 | $278.6 | $504.67 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $230.4 | -$26 | -$475.6 | $579.16 |
News
Fundamentals
| Market cap | $2.27B |
|---|---|
| Enterprise value | $1.96B |
| Shares outstanding | 68.00M |
| Revenue | $78.50M |
|---|---|
| EBITDA | -$359.70M |
| EBIT | -$366.40M |
| Net Income | -$367.30M |
| Revenue Q/Q | -194.52% |
| Revenue Y/Y | -40.26% |
| P/E ratio | -6.19 |
|---|---|
| EV/Sales | 24.98 |
| EV/EBITDA | -5.45 |
| EV/EBIT | -5.35 |
| P/S ratio | 28.98 |
| P/B ratio | 3.43 |
| Book/Share | 9.75 |
| Cash/Share | 4.66 |
| EPS | -$5.40 |
|---|---|
| ROA | -31.79% |
| ROE | -70.24% |
| Debt/Equity | 0.98 |
|---|---|
| Net debt/EBITDA | -0.91 |
| Current ratio | 4.98 |
| Quick ratio | 4.98 |